SillaJen Discusses Collaboration Plans Including Pexa-Vec at BioUSA

On the 3rd to 6th of this month (local time), SillaJen announced on the 11th that it discussed various cooperation plans with global pharmaceutical companies at the BIO International Convention 2024 (BIO USA) held in San Diego, California, USA.

[Photo by Shillajen]

The company explained that this year, it carried out the event schedule with various discussions on more advanced pipelines than before. Pexa-Vec, which completed a Phase 2a clinical trial for kidney cancer patients, held a business meeting with its partner Regeneron. Senior officials from both companies attended the meeting and engaged in in-depth discussions on technology licensing and development expansion. In addition to Regeneron, other global big pharma companies showed interest in the development status and clinical data of Pexa-Vec, leading to further meetings.

Besides Pexa-Vec, meetings were also held regarding BAL0891 and the SJ-600 series, which are under development by SillaJen. These next-generation pipelines attracted inquiries about their mechanisms of action and joint development, and follow-up meetings were established with some companies. A SillaJen representative said, “This BIO USA was a meaningful opportunity to meet with various global companies and introduce the company’s excellent pipelines. In particular, since there were in-depth partnership discussions with some companies regarding our pipelines, we expect to announce good results in the near future.”

This content was produced with the assistance of AI translation services.